RxDoctor Payments Data

Shea Sullivan

Family Medicine · Mesa, AZNPI 1942778246

Payments from drug & device makers

$10,375in general payments, 2019–2025

Across 453 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$2K
  • AstraZeneca$2K
  • Novo Nordisk$942
  • GSK$829
  • AbbVie$538
  • Lilly USA, LLC$501
  • plus $4K from 43 others

What the payments were for

  • Speaking & faculty fees$5956%
  • Food & beverage$9,69893%
  • Education$681%
  • Entertainment$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,375 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$69,682
Medicare patients
290
Services billed
892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone11$532,114
OzempicSemaglutide63$122,356
JardianceEmpagliflozin44$69,867
MounjaroTirzepatide26$53,023
FarxigaDapagliflozin Propanediol31$50,032
GlyxambiEmpagliflozin/Linagliptin25$40,340
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$39,816
TrulicityDulaglutide23$34,549
EliquisApixaban12$18,986
XareltoRivaroxaban12$15,376
TradjentaLinagliptin11$14,655
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,486
Gabapentin151$3,670
Atorvastatin Calcium462$3,643
Levothyroxine Sodium349$3,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$1,703$532,11411 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$380$124,86280 claims
Novo NordiskOzempic$942$122,35663 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,687$89,84870 claims
Lilly USA, LLCMounjaro, Trulicity$501$87,57349 claims
PfizerEliquis$143$18,98612 claims
Johnson & JohnsonXarelto$193$15,37612 claims
AbbVieSynthroid$538$1,28931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →